Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Amylyx Pharmaceuticals Inc’s stock clocked out at $5.81, up 1.93% from its previous closing price of $5.70. In other words, the price has increased by $1.93 from its previous closing price. On the day, 0.79 million shares were traded. AMLX stock price reached its highest trading level at $5.83 during the session, while it also had its lowest trading level at $5.53.
Ratios:
To gain a deeper understanding of AMLX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.66 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 23, 2024, Upgraded its rating to Buy and sets its target price to $10 from $4.20 previously.
On March 18, 2024, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $32 to $4.
Robert W. Baird Downgraded its Outperform to Neutral on March 11, 2024, whereas the target price for the stock was revised from $37 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 30 ’24 when Klee Justin B. sold 18,589 shares for $3.20 per share. The transaction valued at 59,429 led to the insider holds 3,120,569 shares of the business.
Cohen Joshua B sold 18,589 shares of AMLX for $59,414 on Sep 30 ’24. The Co-Chief Executive Officer now owns 3,220,569 shares after completing the transaction at $3.20 per share. On Sep 30 ’24, another insider, Bedrosian Camille L, who serves as the Chief Medical Officer of the company, sold 11,442 shares for $3.20 each. As a result, the insider received 36,559 and left with 143,801 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 395559296 and an Enterprise Value of 88888136. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.32 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 0.298 whereas that against EBITDA is -0.503.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $19.95, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is 66.00%, while the 200-Day Moving Average is calculated to be 21.75%.
Shares Statistics:
It appears that AMLX traded 1.30M shares on average per day over the past three months and 1535940 shares per day over the past ten days. A total of 67.71M shares are outstanding, with a floating share count of 41.21M. Insiders hold about 39.47% of the company’s shares, while institutions hold 69.25% stake in the company. Shares short for AMLX as of 1728950400 were 1010282 with a Short Ratio of 0.78, compared to 1726185600 on 1258866. Therefore, it implies a Short% of Shares Outstanding of 1010282 and a Short% of Float of 1.63.
